TJ DaRenTang USD's stock price surged 3.12% during intraday trading on Thursday, following the release of its first-quarter financial results and new corporate initiatives.
The company reported a 14% year-on-year increase in net profit to RMB423.1 million for Q1 2026, driven by stronger sales in its core traditional Chinese medicine portfolio, which saw revenue grow 7%. The improved profitability was supported by a widening gross margin and lower operating expenses.
Concurrently, the board approved a new 2026 action plan focused on quality improvement, efficiency enhancement, and shareholder returns, while also terminating a previous equity custody agreement. These developments signal a reinforced strategic focus and operational streamlining, likely boosting investor confidence.